Cumberland Pharmaceuticals launches $5.8M at-the-market equity offering with H.C. Wainwright

CUMBERLAND PHARMACEUTICALS INC

ATM program filed March 20, 2024 for up to $5.8M of common stock through H.C. Wainwright as sales agent.
Sales agent will receive 3.0% commission on gross proceeds from shares sold under the agreement.
Proceeds intended for working capital, R&D expenses, capital expenditures, and general corporate purposes.
Sales may occur at prevailing market prices; company may set minimum price or suspend offering at any time.
Offering terminates upon sale of all shares or termination of agreement by either party on five days' notice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.